Corvas down on delayed rNAPc2 timeline

CVAS was off $3.37 (31%) to $7.58 on Tuesday on news that the next stage of clinical studies of its rNAPc2 will be delayed until 2002. CVAS said it is reviewing FDA comments from an end-of-Phase II meeting on the recombinant nematode anticoagulant protein c2 to prevent deep vein thrombosis (DVT) and pulmonary embolism. The company had planned to start Phase III trials this year. ...